ReviewJournal of clinical medicine2014
The Insulin-Like Growth Factor System in Obesity, Insulin Resistance and Type 2 Diabetes Mellitus.
Review in Journal of clinical medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Exploring the Therapeutic Potential of Targeting GH and IGF-1 in the Management of Obesity: Insights from the Interplay between These Hormones and Metabolism.International journal of molecular sciences · 2023Pooled it
- Insulin-like growth factor binding protein-1 and insulin in polycystic ovary syndrome: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- The association between adult height and the incidence of diabetes in a Japanese working population: a prospective study exploring the possible role of cohort effects.BMC public health · 2026Article
- Systematic multi-omic deconvolution of the clinical heterogeneity of Down syndrome.Nature communications · 2026Article
- Obesity and Cancer: From Systemic Metabolic Reprogramming to Immunotherapy Paradox.Metabolites · 2026Review
- IGF-II, IGFBP-4, -6, and -7, and HMGB1 show changes in follicular fluid in PCOS.Frontiers in endocrinology · 2026Article
- Bidirectional regulation of liver sinusoidal clearance by amino acid nanofibers and IGFBP4 complex: effects on HbA1c.Journal of nanobiotechnology · 2025Article
- Long-Term Effects of Semaglutide and Sitagliptin on Circulating IGFBP-1, IGFBP-3 and IGFBP-rp1: Results from a One-Year Study in Type 2 Diabetes.International journal of molecular sciences · 2025Article
- Nutritional Counseling in Children with Growth Hormone Deficiency Treated with Recombinant Human Growth Hormone: Analysis of Growth Response Parameters.Biomedicines · 2025Article
- IGFBP-1 and IGF-I in relation to adiposity and mortality from midlife to old age in the Swedish Adoption/Twin Study of Aging.International journal of obesity (2005) · 2025Article
- Machine learning-based stratification of prediabetes and type 2 diabetes progression.Diabetology & metabolic syndrome · 2025Article
- Therapeutic Potential of Suaeda japonica Makino Leaf Extract Against Obesity in 3T3-L1 Preadipocytes and HFD-Induced C57BL/6 J Mice.Applied biochemistry and biotechnology · 2025Article
- Insulin-Like Growth Factors, Binding Proteins and Their Role in Pregnancy in Patients With Diabetes.Journal of diabetes research · 2025Review
- The Prevalence of Obesity and Metabolic Syndrome among Polish Women without Pre-Existing Cardiovascular Conditions and Diabetes: A Multicenter Study in Poland.Journal of clinical medicine · 2024Article
- Placental IGFBP1 levels during early pregnancy and the risk of insulin resistance and gestational diabetes.Nature medicine · 2024Article
- Gestational Diabetes Mellitus and Colostral Appetite-Regulating Adipokines.International journal of molecular sciences · 2024Article
- Emerging mechanisms of obesity-associated immune dysfunction.Nature reviews. Endocrinology · 2024Review
- Insulin and IGF-1 have both overlapping and distinct effects on CD4Scientific reports · 2024Article
- Explaining Long COVID: A Pioneer Cross-Sectional Study Supporting the Endocrine Hypothesis.Journal of the Endocrine Society · 2024Article
- Targeting Glycolytic Reprogramming in Cholangiocarcinoma: A Novel Approach for Metabolic Therapy.Journal of inflammation research · 2024Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The insulin-like growth factor (IGF) system, acting in concert with other hormone axes, is important in normal metabolism. In obesity, the hyperinsulinaemia that accompanies peripheral insulin resistance leads to reduced growth hormone (GH) secretion, while total IGF-I levels are relatively unchanged due to increased hepatic GH sensitivity. IGF-binding protein (IGFBP)-1 levels are suppressed in relation to the increase in insulin levels in obesity and low levels predict the development of type 2 diabetes several years later. Visceral adiposity and hepatic steatosis, along with a chronic inflammation, contribute to the IGF system phenotype in individuals with metabolic syndrome and type 2 diabetes mellitus, including changes in the normal inverse relationship between IGFBP-1 and insulin, with IGFBP-1 concentrations that are inappropriately normal or elevated. The IGF system is implicated in the vascular and other complications of these disorders and is therefore a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.